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Abstract
Nakalanga syndrome is a condition that was described in Uganda and various other African
countries decades ago. Its features include growth retardation, physical deformities, endo-
crine dysfunction, mental impairment, and epilepsy, amongst others. Its cause remains
obscure. Nodding syndrome is a neurological disorder with some features in common with
Nakalanga syndrome, which has been described mainly in Uganda, South Sudan, and Tan-
zania. It has been considered an encephalopathy affecting children who, besides head nod-
ding attacks, can also present with stunted growth, delayed puberty, and mental impairment,
amongst other symptoms. Despite active research over the last years on the pathogenesis of
Nodding syndrome, to date, no convincing single cause of Nodding syndrome has been
reported. In this review, by means of a thorough literature search, we compare features of
both disorders. We conclude that Nakalanga and Nodding syndromes are closely related and
may represent the same condition. Our findings may provide new directions in research on
the cause underlying this neurological disorder.
The Terms of “Nakalanga” and “Nodding Syndrome”
The term Nakalanga is first found in an anthropological account published by John Roscoe [1]
in 1911, mentioning it as the name of a god recognized by a clan of the Buganda kingdom living
in the area of the Mabira forest located 60 km east of today‘s Ugandan capital city, Kampala. Up
to today, Nakalanga is still the name of a god in the conceptual world of the Baganda [2]. In
addition to this meaning, in a 1934 geographical article about the Mabira forest, the word is
found used to designate a person characterized by a condition of short stature (“dwarfism”),
which was frequently seen in the area [3]. It was suggested that these persons were descendants
of a pygmy tribe that in bygone times would have inhabited the Mabira forest [3,4].
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During the late 1940s, Raper and Ladkin [5] carried out an extensive investigation in the
Mabira forest on patients affected by the Nakalanga phenomenon. They gave a thorough
description of the condition and concluded that their patients were affected by a medical disor-
der, which they called Nakalanga syndrome. Up to 1965, two additional case series were pub-
lished from the same area [6,7]. Thereafter, no more studies were undertaken, and when the
Mabira forest became accessible again in the 1980s, no more cases were found. Instead,
patients with a condition conforming with Nakalanga syndrome were observed in other loca-
tions, namely western Uganda [8–11], Burundi [12], and Ethiopia [13]. This is complemented
by anecdotal observation from other areas of sub-Saharan Africa [14–16], suggesting that the
syndrome is probably not confined to Mabira and southeastern Uganda (Fig 1). As early as
1938, from an area in Mexico where a high endemicity of onchocerciasis and an elevated epi-
lepsy prevalence were found, Casis Sacre described patients affected at a young age by a severe
disorder characterized by growth failure, mental retardation, generalized weakness, and dis-
turbed pubertal development [17]. Although the similarity of this observation with the above-
Fig 1. Map of sub-Saharan Africa. Cases of Nakalanga and Nodding syndrome are reported from onchocerciasis endemic areas
throughout West, Central, and East Africa.
doi:10.1371/journal.pntd.0005201.g001
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mentioned reports was recognized [18], no further investigations from this area are available
to more precisely assess its possible connection with Nakalanga syndrome.
Nodding syndrome is an unexplained neurological disorder with the clinical core feature of
a paroxysmal spell in which the head repeatedly bobs forward for several minutes or longer
[19]. It emerged during the last two decades in then southern Sudan and northern Uganda
[20–26] and, in retrospect, was documented in Tanzania since the 1960s [27,28] and in west-
ern Uganda in 1994 [29]. Reports from Grand Bassa County, Liberia [30], from the Littoral
Province of Cameroon [31], and from the Ituri District in the Orientale Province of the Demo-
cratic Republic of the Congo [32] also point towards the possible existence of Nodding syn-
drome in these areas (Fig 1). A case definition for Nodding syndrome was agreed upon at an
international conference in Kampala, Uganda in 2012 [33]. Because patients with Nodding
syndrome frequently display signs and symptoms that have also been described in Nakalanga
syndrome, it has been questioned if both these conditions represent different manifestations of
a common underlying pathology [21,22,34–37].
In this article, we focus on the following aspects:
• Based on a thorough literature search, we summarize the characteristic clinical features of
Nakalanga syndrome as they were originally described in different areas, and we propose a
working medical definition.
• We summarize available information on the etiology and possible causation of Nakalanga
syndrome.
• We examine the question of whether the symptoms and signs found in Nakalanga syndrome
are also present in cases of Nodding syndrome.
• We give suggestions as to how the relationship between the two entities could be further
studied.
Characterization of Nakalanga Syndrome and a Proposed
Definition
We searched several medical databases (Medline, ScienceDirect, African Neurology Database of
the Institute of Neuroepidemiology of the University of Limoges) using the search term “naka-
langa.” Other sources, such as commercial search engines or unpublished congress proceedings,
were searched without specific limits, and reference lists of retrieved articles and reviews were
screened for further records of relevance (latest search: May 23, 2016). The database search
identified 45 records, and 6 additional records were found from other sources. After removal of
duplicate entries and assessment of relevance, 12 articles were found to present original clinical
data [5–14,38,39]. Three of these were excluded because they contained redundant or insuffi-
cient information [11,38,39]. The remaining nine records [5–10,12–14] represent the evidence
base for a systematic characterization of Nakalanga syndrome (Table 1). A flow diagram
describing the search procedure is available as supporting information (S1 Diagram).
In their pivotal study in the Mabira forest, Raper and Ladkin [5] collected information
from various community members about the local concept of the Nakalanga phenomenon. As
a second step, in a convenience sample of characteristic patients, a list of signs and symptoms
was established, and this was completed by more detailed investigations in seven selected
patients, who were taken to a nearby hospital. Similar studies were carried out by Jellife et al.
[6] and Bagenda et al. [7] in areas neighboring Mabira forest.
As an overall result of these studies, Nakalanga syndrome was specified as a disorder affect-
ing previously healthy children during the first ten years of their life. Growth retardation was
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ii detection of microfilaria of Onchocerca volvulus in skin biopsy, or of antibodies in serology (Newell et al. [12])
iii n.r. = not reported
iv z-score for height-for-age (stunting) and body mass index (BMI) (waisting), referring to 2006 WHO growth standard [40,41]. http://www.who.int/
childgrowth/en/
v no quantified information
vi case report
vii overlap of study populations in studies of Ovuga et al. [8], Kipp et al. [9], and Höfer [10]
viii growth arrest as mandatory symptom, defined as <80% of average height of local population; emaciation as characteristic symptom, not specified
ix mean z-score of height-for-age and BMI, referring to 1977 NCHS growth reference [62]. http://www.cdc.gov/nchs/data/series/sr_11/sr11_165.pdf; Range
not reported
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described as the most prominent feature. When available, we applied height data from the
original publications [5–7,14] to the currently used WHO growth standards [40–42] and
found strikingly similar median z-scores between -4.54 and -4.80 in the case series from these
three closely neighboring areas [5–7], indicating an overall severe degree of stunting (Table 1).
Generally, a height-for-age z-score of more than 2.0 standard deviations below the growth
standard median is considered to indicate stunted growth [40]. Yet, in each of the three studies
[5–7], one patient with a height measurement corresponding to a z-score above the -2.0 stan-
dard deviation threshold was found (z-scores: -1.08, -1.52, and -1.98; Table 1), indicating a
normal stature even when related to the current WHO standard. This is evidence that stunted
growth, although reported as a frequent symptom, was not a mandatory criterion in the con-
cept of the local communities to classify a person as a Nakalanga patient. The height of 53 local
control children was measured by Raper and Ladkin [5] and, expectedly, was found at z-scores
below the current WHO standard (median: -2.14; range: +1.4 to -5.3). Twelve of these 53 chil-
dren had height-for-age z-scores below -3.0, but their overall height was still taller than that of
Nakalanga patients. Emaciation, delayed sexual development, and mental impairment were
described as additional characteristic symptoms of Nakalanga syndrome, although these were
not invariably found in all cases. Some patients also showed facial dysmorphia, deformation of
the vertebral spine, or epileptic seizures (Table 1).
In 1992, Ovuga et al. [8] for the first time described the unusually frequent occurrence of a
condition similar to Nakalanga syndrome in the Itwara onchocerciasis focus, situated in the
Kabarole district, western Uganda (Table 1). The Itwara forest has no contiguity to Mabira for-
est in southeastern Uganda, where Raper and Ladkin had made their primary investigations
40 years earlier [5]. The study of Kipp et al. [9] demonstrated that “Ekihuruka,” as the disorder
was named by the population in the local Rutoro language, was consistent in its clinical picture
with Nakalanga syndrome (Table 1). In 1999, a detailed analysis of 36 patients with Nakalanga
(Ekihuruka) syndrome examined in the mentioned area of the Kabarole district was reported
[10]. A subgroup of 12 of these patients, who in addition were suffering from epilepsy, were
also followed in the study of Kaiser et al. [11,43]. In accordance with the earlier reports from
southeastern Uganda, the study of Höfer [10] demonstrated that patients affected by Naka-
langa (Ekihuruka) syndrome were not solely characterized by growth retardation or another
single sign or symptom alone but rather by the combination of several distinct signs and symp-
toms. Consistent with the anthropometric results from southeastern Uganda [5], the height
measured in a control group of healthy children in western Uganda overlapped with the upper
range of Nakalanga (Ekihuruka) patients [10], although the height-for-age z-score of the con-
trol group (median: -1.09; range: +0.96 to -2.8) was by far higher than that of the patient group
(median: -4.02; range: -1.36 to -6.62; Table 1).
In 1997, Newell et al. [12] in a study from an onchocerciasis endemic area in Burundi
reported cases with retarded growth, mental impairment, and delayed sexual development
among a group of patients identified in an epilepsy survey (Table 1), and they pointed out the
similarity of this observation with Nakalanga syndrome. In a study on clinical features of
onchocerciasis in Ethiopia, Oomen described an individual patient showing a striking similar-
ity with Nakalanga syndrome as found in southeastern Uganda [13].
The consistent syndromic pattern found in the mentioned noncontingent areas indicates
that the reported patients may be affected by the same neurological disorder. Based on these
findings, we propose that Nakalanga syndrome can be defined as a disorder affecting young
children and youths who were born healthy and have passed through an initial phase of
healthy development (Table 2). Patients present with at least one of the following predominant
symptoms: retardation of growth (stunting), emaciation (wasting), delayed sexual develop-
ment, or mental impairment. Less frequently, facial dysmorphia with small mandible, large
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lips, protruding front teeth, kyphoscoliosis, or epileptic seizures are encountered along with
the mentioned major signs and symptoms. In the environment of a patient with Nakalanga
syndrome, an accumulation of other cases with similar features is found.
Information on Etiology and Possible Causes of Nakalanga
Syndrome
In view of the clinical picture and the epidemiologic distribution, Raper and Ladkin [5]
excluded the hypothesis that people with Nakalanga syndrome could belong to a pygmy tribe.
The combination of their clinical observations with the finding of a low urinary excretion of
the 17-ketosteroids led them to assume that Nakalanga syndrome should be induced by defects
in pituitary and adrenal gland function. In 1961, Marshall and Cherry [14] reported on an
autopsy case which revealed no major changes of the histological appearance of the adrenal
gland compatible with major adrenal dysfunction. In the histology of the pituitary gland of
this case, they described some alterations in the composition of acidophil, basophil, and chro-
mophobe cells, but the vascular supply was not disturbed, and there was no major lesion found
that could have been produced by invasion of a pathogenic agent, e. g., Onchocerca volvulus
microfilaria. It was concluded that “the primary affection may have been either in the pituitary
portal system or the hypothalamus,” and the authors speculated that the “humoral transmis-
sion through the pituitary portal system was possibly jeopardized by circulating products of
dead microfilaria” [14]. In a series of ten Nakalanga patients, Leonard and Stanfield [39] found
normal levels of morning plasma cortisol and a normal protein binding fraction of cortisol.
They also reported normal results of fasting serum growth hormone (GH) in two patients and
a normal rise of GH in a third case following stimulation with injected insulin [39]. In the
studies from Burundi [12] and from western Uganda [10], thyroid-stimulating hormone
(TSH) as well as total thyroxine (T4) and triiodothyronine (T3) levels were measured and nor-
mal values were found in 31 of 32 cases. Höfer [10] also investigated the serum concentration
of insulin-like growth factor I (IGF-I) and IGF-binding-protein-3 (IGF-BP-3) in a group of 23
severely stunted Nakalanga patients and found slightly lower concentrations in patients than
Table 2. Proposed criteria for definition of Nakalanga syndrome compared to criteria for definition of
a probable case of Nodding syndrome consented in Kampala 2012 (adapted from ref. [26,33]).
Proposed criteria for Nakalanga syndrome Consented criteria for Nodding syndrome
Major criteria (obligatory) Major criteria
1. Born healthy 1. Reported head nodding in a previously healthy person
2. Onset in childhood 2. Age 3–18 y at onset of head nodding
3. No alternative explanatory condition 3. Nodding frequency 5–20 times/min
4. Plus, one or several symptoms of
developmental disturbance:
a) Stunting, growth failure
b) Wasting, emaciation
c) Retardation of sexual development
d) Mental impairment
Minor criteria (additional) Minor criteria
5. Facial dysmorphia: small and protuberant
mandible, large lips, protruding front teeth
4. Other neurological abnormalities (cognitive, school
dropout, other seizures, or neurological abnormalities)
6. Kyphoscoliosis 5. Clustering in space or time with similar cases
7. Epileptic seizures 6. Delayed sexual or physical development
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controls, but IGF-I levels were not compatible with GH deficiency in 16 cases. When the
remaining seven patients were assessed case-by-case with GH determination after physical
strain and a follow-up of their growth rate over one year, GH deficiency was excluded in three
more patients. In agreement with the findings of Leonard and Stanfield [39], and contrasting
with the earlier assumptions of Raper and Ladkin [5], the results of Höfer [10] disprove the
hypothesis that a primary pituitary lesion plays a causative role in the pathophysiology of
Nakalanga syndrome.
When Nakalanga syndrome was first recognized in the 1950s as a regional medical entity
[5–7], a search on the cause of the condition was undertaken with the resources available at the
time. On the ground of their clinical, laboratory, and epidemiological findings, the authors
of the three studies from Southeast Uganda widely excluded a number of chronic disorders
that elsewhere in Uganda or tropical Africa had been found related with growth failure [5–7].
Explicitly, they found no connection with malaria, malnutrition, tuberculosis, rickets, syphilis,
blood dyscrasias, intestinal parasites, and chronic diseases of the liver or other organs, but viral
etiologies or auto-immune disorders were not mentioned. In view of the sporadic distribution
of patients in different ethnic groups and families, a genetic disorder was considered unlikely,
although this was not fully excluded [6]. Consistent with the findings from southeastern
Uganda, no known disorder could be identified which possibly caused growth failure in Naka-
langa (Ekihuruka) patients in western Uganda [9,10]. As a consistent observation, all study
areas were found highly infested with onchocerciasis (Table 1).
Little is known about the natural history and the prognosis of Nakalanga syndrome.
According to Raper and Ladkin [5], after the onset in early childhood, the symptoms progress
to reach a peak during adolescence. In some patients, the physical and mental condition visibly
deteriorates to the extent of severe wasting and progressive loss of mental function. It seems
likely that Nakalanga syndrome results in increased mortality, and this is supported by the
observation that few, if any, Nakalanga patients older than 30 years were reported in the vari-
ous studies (Table 1). In the cohort of 12 patients in western Uganda, who in addition to Naka-
langa (Ekihuruka) syndrome were also suffering from epilepsy, a high mortality was found
[11]. No comparable data have been assessed from Nakalanga patients without associated epi-
lepsy. Contrasting with the observation of an obviously severe course of the disease in many
patients, it has also been stated that some Nakalanga patients “may reach an advanced age” [5]
or “appear to live a normal life” [6].
Comparison between Nakalanga Syndrome and Nodding Syndrome
A second literature search for records presenting original clinical information on patients
with Nodding syndrome retrieved 20 publications [19–25,28,29,44–54]. Nine of these were
excluded from the analysis [19,22,24,25,46–48,51,52] because they presented incomplete data
or redundant information, which was found in more detail in another article. The remaining
11 articles were systematically screened for symptoms and signs, which beforehand had been
identified as characteristic for Nakalanga syndrome (Table 3). Details of the search procedure
and a flow diagram is available as supporting information (S2 Diagram).
The age of Nodding syndrome patients at examination in cross-sectional studies, as well as
the reported age at onset of the disorder, coincided well with that of patients affected by Naka-
langa syndrome. Growth retardation and wasting as the most prominent features of Nakalanga
syndrome were reported in the majority of published studies on Nodding syndrome, although
exact measurements were only provided in two studies [29,50]. All studies on the clinical char-
acteristics of Nodding syndrome also found mental impairment of varying degrees in a part of
their patients, and all found patients with other epileptic seizures in addition to head nodding
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seizures. Disturbance of pubertal development, spine deformity, or facial dysmorphia were
documented only exceptionally in patients with Nodding syndrome, but these features were
not systematically investigated in all studies. The findings of Table 3 document the intriguing
overlap between Nakalanga and Nodding syndromes, but hitherto available data are fragmen-
tary and, in part, were established with poorly defined methods.
A recent study from northern Uganda [50] determined various endocrinological parame-
ters in a series of eight patients with Nodding syndrome with different degrees of stunted
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growth and delayed puberty. Normal values were found for morning cortisol, TSH, and T4
in all patients. IGF-1 levels were generally low but within the normal range in five of eight
patients, and serum GH—determined without stimulation—was normal. Gonadotropin levels
were within the range of the clinically delayed stages of puberty. These results are consistent
with those from patients with Nakalanga syndrome examined in southeastern Uganda [39],
western Uganda [10], and Burundi [12]. As the authors state, pituitary stimulation tests are
needed to better differentiate the role of hypothalamic and pituitary factors in inducing growth
failure and hypogonadism in Nodding syndrome patients [50].
Our working definition of the Nakalanga syndrome shows an intriguing similarity to that
of Nodding syndrome [33]: both conditions have their onset from an early age, are frequently
combined with mental retardation, and there is a striking overlap in the symptom of growth
failure as the predominant feature in Nakalanga patients. The patient with Nodding syndrome
reported by Kaiser et al. [29] was also found severely stunted and considered by the commu-
nity to suffer from Nakalanga syndrome, locally known as “Ekihuruka” [9,10]. This case report
illustrates that Nakalanga and Nodding syndromes occur concomitantly in this area in western
Uganda [8–11,29]. Possibly, some of the patients with Nakalanga syndrome reported 40 years
earlier from southeastern Uganda were also affected by head nodding attacks. This is indicated
by the description of Raper and Ladkin [5] that “inability to hold up the head is taken as a sign
of a severe affection” and “certain cases would let the head fall forwards while eating and be
quite incapable of raising it again.”
Another shared trait between Nodding and Nakalanga syndrome is the association with
onchocerciasis, although this does not necessarily imply causality. All study areas where cases
of either condition were reported were also highly endemic for onchocerciasis, and, when this
was investigated, infection with O. volvulus was consistently more frequent in patients than in
controls [9,10,21,22,25,46]. The isolated observation of a disorder reminiscent of Nakalanga
syndrome from an onchocerciasis endemic area in Mexico could also be seen as corroboration
of this association [17]. A close relationship between onchocerciasis and convulsive epilepsy
has also been found in areas with and without confirmed Nodding syndrome [34,55], and
there is indication that in these areas intensity of infection is involved in the induction of epi-
lepsy [16,34,56]. So far, the issue of O. volvulus infection intensity has not been specifically
examined in studies on Nodding or Nakalanga syndrome, but Raper and Ladkin pointed out
their impression that Nakalanga patients “were more early and more heavily parasitised than
their fellows” [5].
As a limitation to the assumption of a possible causative relationship between Nakalanga
syndrome/Nodding syndrome and onchocerciasis, it is highly interesting that in many O.
volvulus endemic areas, a single case of one of these two disorders was never reported. It has
also not been clarified whether infection with O. volvulus actually precedes the onset of head
nodding or growth retardation, because the relationship between onchocerciasis was so far
investigated solely with cross-sectional studies. It may well be that Nodding and/or Naka-
langa syndrome are due to an alternative pathogenic agent, potentially transferred by the
same vector as O. volvulus. Affected children could be particularly susceptible to infection
with onchocerciasis, which would then be a natural consequence rather than the cause of
these disorders. As far as possible pathological mechanisms were investigated, the presence
of the parasite, or evidence on an inflammatory or immune reaction to the parasite in the
central nervous system, could not be verified neither in patients with Nodding syndrome
[19,21,23,24,57,58] nor in the mentioned autopsy case affected by Nakalanga syndrome
[14].
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Conclusions and Recommendations
Many aspects of Nakalanga and Nodding syndromes and their possible interrelation remain
unsolved. One important question that needs to be addressed is the determination of the hith-
erto unknown frequency and the extent of growth failure in patients with Nodding syndrome
in those areas where it was first confirmed—South Sudan, northern Uganda, and Tanzania. It
is also unclear why in these areas no patients presenting with growth failure, delayed puberty,
and mental retardation but without head nodding were reported, as this was demonstrated in
southeastern as well as in western Uganda. We suggest that the characteristic features of Naka-
langa syndrome should be more systematically investigated in patients with Nodding syn-
drome. It would also be of interest to find out whether the communities affected by Nodding
syndrome also know about an illness in their area which is primarily characterized by growth
failure and which might correspond to Nakalanga syndrome. We consider it of importance
that studies on this issue uniformly refer to the generally consented 2012 Kampala case defini-
tion of Nodding syndrome [33,59] and that the effective ILAE guidelines for epidemiologic
studies are followed [60]. Although sophisticated diagnostic tools such as video monitoring
including electroencephalography (EEG) or brain imaging are not readily available in the set-
ting of rural sub-Saharan Africa, seizures could be documented with mobile phone video and
mobile EEG machines. These tools would be useful to confirm the diagnosis of Nodding syn-
drome in suspected cases. We want to encourage more neurological researchers to seek the
collaboration of interested local colleagues to establish a dataset for neurophysiological records
that could be reevaluated remotely by African and non-African experts alike.
Our proposed definition of the Nakalanga syndrome deliberately does not formulate spe-
cific criteria for confirmation of the disorder in the individual patient. We hope that our pro-
posal will further develop on the basis of future research, and the contributions of others will
help to improve its practicality. At present, we consider it of importance that the major fea-
tures configuring Nakalanga syndrome—stunting, wasting, delayed sexual development, and
mental impairment—should be assessed with clearly defined methodological approaches.
Anthropometric measurements of height and weight should be carried out in patients, and in
local controls, and should be related to the current standards of WHO [40–42]. These were
developed with recent multicenter surveys and are recommended to replace earlier reference
databases [61,62]. Definite clinical methods for the assessment of pubertal stages were devel-
oped with the basic studies of Marshall and Tanner [63,64], and these have been successfully
applied in northern Uganda [50,65]. Because of the great diversity of regulating influences on
the development of puberty [66–70], universal standards on the age at onset and the chrono-
logical sequence of pubertal stages are not available. It would therefore be crucial to always
include carefully matched local controls in study protocols. The development and validation of
more diagnostic tools on mental function would help to generate comparable results in differ-
ent studies.
Taken together, we find evidence that Nakalanga syndrome and Nodding syndrome are
closely related and may even be two manifestations of one underlying, yet unclear, pathology.
According to the metaphoric hypothesis formulated by Wamala et al. [71] that “Nodding syn-
drome may be only the ears of the hippo,” Nakalanga syndrome may emerge to be one of these
ears, i.e., the other end of a disease continuum. However, we want to caution against adoption
of the premature conclusion that onchocerciasis is confirmed as the cause of Nodding—or
Nakalanga—syndrome [72]. A multidisciplinary approach of researchers from various fields
will be needed to find answers to the many unsolved questions connected with this (these)
mysterious brain disorder(s).
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Key Learning Points
• Nakalanga and Nodding syndromes both are developmental disorders of unknown
cause affecting children and adolescents in onchocerciasis endemic areas of sub-Saha-
ran Africa.
• Predominant features of Nakalanga syndrome are stunted growth, delayed pubertal
development, and mental impairment—and epileptic seizures in a proportion of cases.
• Nodding syndrome is characterized by paroxysmal head nodding, frequently accom-
panied by mental decline—and stunted growth, delayed puberty, and convulsive sei-
zures in a proportion of cases.
• Our review provides evidence that both syndromes are closely related and may repre-
sent manifestations of one underlying disease.
• We propose the use of clearly described multidisciplinary methods to clarify the rela-
tionship between these enigmatic disorders and their underlying pathology.
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